VF in the News

Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

PUBLISHED 11 September 2023 First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared…...

Read more

US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica

The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. Kevzara has been approved as the first and only biologic indicated for PMR adult patients who did not respond to corticosteroids or who cannot tolerate corticosteroid taper. Developed using…...

Read more

Amgen Successfully Completes Acquisition of ChemoCentryx

TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...

Read more

Mom Climbs Highest Mountain in Africa in Memory of Her Extraordinary Daughter

Update: Jo has made it to the top of Mt. Kilimanjaro! The climb was by far the hardest thing she’s ever had to face other than losing her daughter, Amy, to vasculitis. “They call it ‘The Roof of Africa’ but I call it almost to heaven! It’s the closest I’ll…...

Read more